The PI3K/AKT inhibition by Idelalisib unexpectedly induces GSK3/FOXO1 activation, leading to the upregulation of IGF1R, which in turn activates the MAPK signaling in the Idelalisib-treated tumor cells. The gene discussed is IGF1R; the disease is neoplasm.